Hospital
Ashley Valley Medical Center LLC
Ashley Valley Medical Center LLC was paid $4.44M by Medicaid between Jan 2018 and Oct 2024, across 133 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 56% of everything it billed.
33Billing provider infoASHLEY VALLEY MEDICAL CENTER LLC
VERNAL, UT 84078
VERNAL, UT 84078
33aNPI1447296249assigned 06/21/2006
33bProvider typeRural Acute Care Hospital
28Total paid$4.44M
24GClaims150,089
24DCodes billed133
24AFirst – last monthJan 2018 – Oct 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,330 | $418K | |
| 2019 | 26,322 | $665K | |
| 2020 | 29,648 | $726K | |
| 2021 | 36,268 | $1.25M | |
| 2022 | 32,238 | $1.09M | |
| 2023 | 2,829 | $139K | |
| 2024incomplete | 1,454 | $149K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 56% | 2,898 | 1,586 | $2.48M |
| 36415 | Collection of venous blood by venipuncture | 9.1% | 5,748 | 5,089 | $402K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.6% | 9,699 | 8,309 | $295K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.2% | 2,096 | 1,913 | $144K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 1,089 | 1,027 | $110K |
| 80053 | Comprehensive metabolic panel | 2.3% | 10,652 | 8,755 | $102K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2.3% | 2,853 | 2,476 | $101K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.1% | 1,462 | 1,397 | $93K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.0% | 5,637 | 5,036 | $87K |
| 87400 | 1.1% | 2,242 | 1,156 | $48K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 2,161 | 1,832 | $48K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,281 | 2,956 | $44K |
121 more codes
| 81001 | <1% | 6,621 | $37K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 734 | $32K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,724 | $29K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 415 | $29K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,088 | $27K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 72 | $22K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,352 | $19K |
| 87430 | <1% | 1,384 | $19K | |
| 87510 | <1% | 117 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,319 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,298 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 965 | $13K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,184 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 155 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,589 | $11K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 139 | $11K |
| 82962 | <1% | 953 | $10K | |
| 87077 | <1% | 1,067 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 196 | $10K |
| 99285 | Emergency room visit (most serious) | <1% | 3,142 | $9K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 759 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 738 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,133 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,706 | $6K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 169 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,103 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 970 | $6K |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 81 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 41 | $5K |
| 90715 | <1% | 30 | $5K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,482 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 525 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 289 | $4K |
| 87070 | <1% | 144 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,261 | $3K |
| 81025 | <1% | 749 | $3K | |
| 73130 | <1% | 58 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 995 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,896 | $3K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 41 | $3K |
| 84439 | <1% | 841 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,257 | $2K |
| 80061 | Lipid panel | <1% | 411 | $2K |
| 87420 | <1% | 539 | $2K | |
| 84703 | <1% | 1,750 | $2K | |
| 73564 | <1% | 27 | $2K | |
| 73110 | <1% | 30 | $1K | |
| 73030 | <1% | 57 | $1K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 627 | $1K |
| 73630 | <1% | 50 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,536 | $1K |
| 73610 | <1% | 27 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 63 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 14 | $1K |
| 80055 | <1% | 26 | $941.99 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 948 | $798.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 806 | $708.62 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 179 | $643.61 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 14 | $622.34 |
| 88150 | <1% | 80 | $615.98 | |
| 76801 | <1% | 14 | $570.45 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 593 | $493.58 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 267 | $443.64 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 418 | $360.69 |
| 84702 | <1% | 149 | $360.42 | |
| 82950 | <1% | 24 | $359.30 | |
| 86900 | <1% | 179 | $356.74 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,867 | $348.06 |
| 87081 | <1% | 28 | $330.64 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 966 | $300.55 |
| 86140 | <1% | 591 | $263.65 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 365 | $223.65 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 98 | $151.98 |
| 85379 | <1% | 807 | $147.53 | |
| 86803 | <1% | 16 | $133.13 | |
| 87653 | <1% | 27 | $113.33 | |
| 86850 | <1% | 38 | $108.29 | |
| 83735 | <1% | 1,770 | $98.00 | |
| 82550 | <1% | 1,122 | $84.53 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 270 | $74.96 |
| 84484 | <1% | 2,429 | $74.46 | |
| 83880 | <1% | 514 | $58.27 | |
| 83690 | <1% | 2,092 | $56.97 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 521 | $48.76 |
| 85610 | <1% | 1,490 | $36.55 | |
| 85027 | <1% | 739 | $29.91 | |
| 87186 | <1% | 815 | $17.87 | |
| 85730 | <1% | 764 | $16.21 | |
| 87040 | <1% | 766 | $15.02 | |
| 83605 | <1% | 572 | $11.14 | |
| 84100 | <1% | 533 | $10.64 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 65 | $8.92 |
| 87660 | 0% | 117 | $0.00 | |
| 84145 | 0% | 255 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 14 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 28 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 24 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 16 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 484 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 108 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 908 | $0.00 |
| A9270 | Non-covered item or service | 0% | 14 | $0.00 |
| 96376 | 0% | 796 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 171 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 263 | $0.00 |
| 85652 | 0% | 97 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 250 | $0.00 |
| 87480 | 0% | 117 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 139 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 12 | $0.00 |
| 86901 | 0% | 179 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 42 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 30 | $0.00 |
| 94760 | 0% | 70 | $0.00 | |
| 87205 | 0% | 104 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 57 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 15 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 29 | $0.00 |
| 74019 | 0% | 12 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRRENCE, CHARLOTTE (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Raleigh General Hospital LLC | Beckley, WV | $916K |
| Athens Physicians Practice, LLC | Athens, TN | $667K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.